Sanofi EPS - Earnings per Share 2012-2025 | SNY
Sanofi annual and quarterly earnings per share history from 2012 to 2025. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Sanofi EPS for the quarter ending September 30, 2025 was $1.34, a 8.65% increase year-over-year.
- Sanofi EPS for the twelve months ending September 30, 2025 was $4.17, a 113.24% increase year-over-year.
- Sanofi 2024 annual EPS was $2.4, a 3.01% increase from 2023.
- Sanofi 2023 annual EPS was $2.33, a 33.68% decline from 2022.
- Sanofi 2022 annual EPS was $3.51, a 19.84% increase from 2021.
| Sanofi Annual EPS | |
|---|---|
| 2024 | $2.40 |
| 2023 | $2.33 |
| 2022 | $3.51 |
| 2021 | $2.93 |
| 2020 | $5.58 |
| 2019 | $1.25 |
| 2018 | $2.03 |
| 2017 | $3.76 |
| 2016 | $2.01 |
| 2015 | $1.81 |
| 2014 | $2.19 |
| 2013 | $1.85 |
| 2012 | $2.41 |
| 2011 | $2.83 |
| Sanofi Quarterly EPS | |
|---|---|
| 2025-09-30 | $1.34 |
| 2025-06-30 | $1.84 |
| 2025-03-31 | $0.80 |
| 2024-12-31 | $0.19 |
| 2024-09-30 | $1.24 |
| 2024-06-30 | $0.48 |
| 2024-03-31 | $0.49 |
| 2023-12-31 | $-0.25 |
| 2023-09-30 | $1.10 |
| 2023-06-30 | $0.63 |
| 2023-03-31 | $0.86 |
| 2022-12-31 | $1.27 |
| 2022-09-30 | $0.84 |
| 2022-06-30 | $0.50 |
| 2022-03-31 | $0.90 |
| 2021-09-30 | $1.09 |
| 2021-06-30 | $0.00 |
| 2021-03-31 | $0.75 |
| 2020-09-30 | $0.91 |
| 2020-03-31 | $0.75 |
| 2019-09-30 | $0.78 |
| 2019-03-31 | $0.52 |
| 2018-03-31 | $0.50 |
| 2017-12-31 | $0.17 |
| 2017-09-30 | $0.74 |
| 2017-06-30 | $0.45 |
| 2017-03-31 | $2.41 |
| 2016-12-31 | $0.31 |
| 2016-09-30 | $0.73 |
| 2016-06-30 | $0.51 |
| 2016-03-31 | $0.46 |
| 2015-09-30 | $0.70 |
| 2015-06-30 | $0.55 |
| 2014-06-30 | $0.41 |
| 2013-06-30 | $0.22 |
| 2012-06-30 | $0.57 |
| 2012-03-31 | $0.91 |
| 2011-12-31 | $0.71 |
| 2011-09-30 | $1.05 |
| 2011-06-30 | $0.56 |
| 2011-03-31 | $1.22 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $115.780B | $44.458B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $976.553B | 46.97 |
| Johnson & Johnson (JNJ) | United States | $529.009B | 21.15 |
| AbbVie (ABBV) | United States | $383.081B | 22.94 |
| Roche Holding AG (RHHBY) | Switzerland | $344.774B | 0.00 |
| Novartis AG (NVS) | Switzerland | $302.393B | 16.03 |
| Merck (MRK) | United States | $275.430B | 12.83 |
| Novo Nordisk (NVO) | Denmark | $255.041B | 14.95 |
| Pfizer (PFE) | United States | $147.203B | 8.09 |
| Bayer (BAYRY) | Germany | $47.824B | 8.39 |
| Innoviva (INVA) | United States | $1.477B | 7.40 |